Metformin Can Significantly Reduce COVID-19 Death Risks In W
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A retrospective cohort analysis published in The Lancet Healthy Longevity found that metformin was associated with significantly reduced COVID-19 death risks in women.

The team analyzed whether or not metformin use was associated with decreased mortality in 6,000 individuals with type 2 diabetes or obesity who were hospitalized with COVID-19.

They found an association that women with diabetes or obesity who had filled a 90-day metformin prescription before hospitalization had a 21% to 24% reduced likelihood of mortality compared to similar women not taking the medication. The results provide new directions for research against COVID-19.

Bramante, the principal investigator in collaboration with Christopher Tignanelli, MD, assistant professor in the Department of Surgery at the University of Minnesota Medical School submitted an investigational new drug application to the FDA for use of metformin for COVID-19 treatment and prevention.

The FDA approved this application and this pilot trial will begin enrolling the week of Dec. 8 and will lead into a larger trial.

Source:
https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(20)30033-7/fulltext
D●●●●●●a S●●●h and 3 others like this8 shares
Like
Comment
Share